Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963715 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
A Phase 1 study, sponsored by ImmunoGen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01963715: Clinical Trial Phase 1 study, sponsored by ImmunoGen.
NCT01963715 is a Phase 1 study that was terminated before completion, run by ImmunoGen. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01963715, a Phase 1 study, was terminated before completion, sponsored by ImmunoGen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
Interventions
- DRUG IMGN289
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Why NCT01963715 stopped before completion
NCT01963715 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which IMGN289 is the first listed.
NCT01963715 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01963715 about?
NCT01963715 is a clinical study titled "A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors". This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
What is the current status of trial NCT01963715?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-10. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01963715?
The interventions under investigation include: IMGN289 (DRUG).
Who is sponsoring clinical trial NCT01963715?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01963715's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia